Teva Pharmaceuticals Had a Very Bad Day, in a Very Bad Year

In this Market Foolery 160 podcast segment host Chris Hill and Motley Fool One s Bill Mann consider how much worse Teva Pharmaceutical Industries NYSE TEVA 160 looks presently after a second quarter report that featured weak sales low profits a 75 dividend